NASDAQ · TRIB
Healthcare · Medical - Diagnostics & Research
$8.00
Down-$0.31 (-3.81%)
Updated Sep 10, 2026, 2:44 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TRIB closed at $8.00 after 20 trading sessions, down 31.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $9.4708 | $9.52 | $8.00 | $8.00 | 27.24K |
| Sep 8, 2026 | $9.31 | $9.671 | $8.8022 | $9.06 | 10.06K |
| Sep 4, 2026 | $9.50 | $9.84 | $9.2402 | $9.41 | 11.24K |
| Sep 3, 2026 | $9.62 | $9.90 | $9.235 | $9.60 | 20.37K |
| Sep 2, 2026 | $9.60 | $9.85 | $9.45 | $9.60 | 12.07K |
| Sep 1, 2026 | $9.76 | $9.95 | $9.325 | $9.72 | 10.04K |
| Aug 31, 2026 | $9.61 | $10.205 | $9.51 | $9.87 | 14.55K |
| Aug 28, 2026 | $9.83 | $9.83 | $9.2976 | $9.68 | 6.67K |
| Aug 27, 2026 | $9.86 | $10.32 | $9.75 | $9.75 | 11.25K |
| Aug 26, 2026 | $9.71 | $10.035 | $9.49 | $9.59 | 28K |
| Aug 25, 2026 | $10.98 | $10.98 | $9.6901 | $9.71 | 66.78K |
| Aug 24, 2026 | $10.48 | $10.59 | $10.0001 | $10.33 | 6.86K |
| Aug 21, 2026 | $10.95 | $11.245 | $10.285 | $10.60 | 8.11K |
| Aug 20, 2026 | $11.19 | $12.10 | $10.25 | $10.55 | 16.85K |
| Aug 19, 2026 | $12.12 | $12.25 | $10.3958 | $11.01 | 55.48K |
| Aug 18, 2026 | $11.15 | $13.20 | $11.15 | $12.43 | 127.06K |
| Aug 17, 2026 | $11.56 | $11.80 | $11.09 | $11.17 | 11.22K |
| Aug 14, 2026 | $12.9899 | $12.9899 | $11.5001 | $11.67 | 24.46K |
| Aug 13, 2026 | $11.2977 | $12.2199 | $11.2977 | $11.87 | 74.53K |
| Aug 12, 2026 | $13.01 | $13.01 | $11.2535 | $11.65 | 56.3K |
The latest Smart Investors Daily articles mentioning TRIB.
TRIB research
Company profile and research snapshot.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2016 | Stephens & Co. | Equal-weight | — |
| Oct 5, 2016 | Stephens & Co. | Equal-weight | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
The Company also announced that it has regained compliance with Nasdaq’s minimum bid price requirement, marking another positive development as Trinity Biotech continues to execute its strategic priorities.Perceptive
Benzinga · Jul 22, 2026
The collaboration is intended to combine data streams from Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's advanced drug delivery technologies to evaluate the development of precision
Benzinga · Jul 22, 2026
For Trinity Biotech Plc ADS holders, the change in the ADS ratio will have the same effect as a one for-thirty reverse ADS split and is intended to i) enable the Company to regain compliance with the $1.00 Nasdaq
Benzinga · Jul 2, 2026
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows- Demonstrates
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TRIB.
No results
No recent SID articles mention TRIB.
